K2-D3 with Astaxanthin Ingredients & Drug Interactions
What is this page for?
First and foremost: checking K2-D3 with Astaxanthin against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
K2-D3 with Astaxanthin is a dietary supplement by Douglas Laboratories with 3 active ingredients. Its ingredients are commonly taken for bone health and osteoporosis, correcting vitamin d deficiency, immune system support.Based on those ingredients, 743 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Vitamin D3, AstaReal, Vitamin K2. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against K2-D3 with Astaxanthin by Douglas Laboratories
Ask about any prescription or over-the-counter medication and we check it for interactions with K2-D3 with Astaxanthin by Douglas Laboratories — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of K2-D3 with Astaxanthin by Douglas Laboratories
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Full disclosure
This product contains 3 active ingredients. Vitamin D3 is a fat-soluble nutrient that helps your body absorb calcium and maintain bone health and immune function.
Vitamin K2 is a form of vitamin K involved in blood clotting and bone metabolism. Astaxanthin (AstaReal brand) is a red carotenoid antioxidant found in certain algae and seafood.
The capsule also contains inactive ingredients — microcrystalline cellulose, hydroxypropyl methylcellulose, and vegetable stearate — which are standard binders, thickeners, and lubricants used in supplement manufacturing.
Does it work?
Strong evidence
Vitamin D3 is effective for treating rickets, osteomalacia (soft bones from vitamin D deficiency), renal osteodystrophy (bone disease from kidney problems), hypoparathyroidism (low parathyroid hormone), and familial hypophosphatemia (inherited low phosphate). Vitamin K2 is effective for hypoprothrombinemia (a clotting-factor deficiency), vitamin K-dependent clotting-factor deficiency, warfarin-related anticoagulation management, and hemorrhagic disease.
For osteoporosis, vitamin K2 shows possibly effective evidence. Astaxanthin's effectiveness is not established in our data.
We have insufficient reliable evidence to rate it for age-related cognitive decline, macular degeneration (AMD), aging skin, Alzheimer disease, athletic performance, carpal tunnel syndrome, or other conditions you may be considering it for.
How safe is it?
Well-documented data
Vitamin D3 is generally well tolerated at recommended doses, though very high doses over time can cause vitamin D toxicity with symptoms of high blood calcium (hypercalcemia), kidney problems (azotemia), anemia, and bone loss in adults or slowed growth in children. Serious adverse effects are rare but include eye inflammation (calcific conjunctivitis) and light sensitivity (photophobia).
Vitamin K2 is generally well tolerated orally; the most common side effects are mild — nausea, diarrhea, stomach upset, and abdominal pain. Astaxanthin is generally well tolerated in studies, though long-term safety data are limited.
Common side effects include abdominal pain, diarrhea, and red-colored stools; at higher doses (40 mg daily), severe abdominal pain has been reported in a small number of trial participants. For pregnancy: Vitamin D3 is likely safe at recommended amounts but only under your doctor's guidance; the data also flag it as possibly unsafe, so clarify the right dose with your provider.
Vitamin K2 is likely safe during pregnancy and lactation. Astaxanthin has insufficient data — it's best to avoid it during pregnancy and breastfeeding.
Talk with your doctor before taking this product if you're pregnant or nursing.
Meds to double-check
Major interaction found
Before taking this product, check with your doctor or pharmacist if you take warfarin (a blood thinner) — this is a Major interaction. You should also double-check if you're on thiazide diuretics, verapamil, diltiazem, digoxin, atorvastatin, calcipotriene, or any medications metabolized by CYP3A4 or CYP2B6 liver enzymes, as vitamin D3 and astaxanthin carry Moderate interactions with these drug types.
Use the medication checker below to search your exact prescriptions.
The bottom line
Scorecard at a glanceFully disclosed formula with strong clinical evidence behind its ingredients' uses. Major medication interactions have been identified, and safety information is well characterized.
K2-D3 with Astaxanthin is designed to support bone health and clotting function through two well-established nutrients. It's not appropriate if you take warfarin (a blood thinner), and you'll need to check with your doctor before starting if you're on thiazide diuretics, heart-rhythm medications, digoxin, atorvastatin, or psoriasis treatments — or if you take high-dose vitamin D already.
Talk with your doctor or pharmacist about whether this product is right for your medications and health situation.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 3 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Sep 22, 2022.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about K2-D3 with Astaxanthin, straight from the product label.
| Brand | Douglas Laboratories |
|---|---|
| Barcode (UPC) | 310539040638 |
| Net contents | 30 Vegetarian Capsule(s) |
| Market status | On market |
| Date entered into DSLD | Sep 22, 2022 |
| DSLD ID | 274066 |
| Product type | Other Combinations |
| Supplement form | Capsule |
| Dietary claims / uses | All Other, Structure/Function |
| Intended target group(s) | Adult (18 - 50 Years), Gluten Free |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for K2-D3 with Astaxanthin by Douglas Laboratories, sourced from the NIH Dietary Supplement Label Database.
Supplement Facts
| Ingredient | Amount | % DV |
|---|---|---|
| Vitamin D3 | 62.5 mcg | 313% |
| Vitamin K2 | 180 mcg | -- |
| AstaReal | 2 mg | -- |
Other ingredients: Microcrystalline Cellulose, Hydroxypropyl Methylcellulose, Vegetable Stearate
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions
Suggested Usage: Adults take 1 capsule daily with a meal, or as directed by your health professional.
Precautions
Warning: If you are pregnant, nursing, have any health condition or taking any medication, particularly blood thinners, consult your health professional before using this product.
Note: People consuming more than 50 mcg (2,000 IU) per day should have their vitamin D blood levels monitored by a health professional.
Keep out of the reach of children.
Use only if safety seal is intact.
Brand IP Statement(s)
AstaReal is a registered trademark of Fuji Chemical Industries Co., Ltd. K2VITAL is a registered trademark of Kappa Bioscience AS
Storage
Store in a cool, dry place.
Formulation
Gluten-free, Non-GMO
Cardiovascular and bone health
FDA Disclaimer Statement
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
General Statements
Scan to learn about our manufacturing excellence Contents may not fill package in order to accommodate required labeling. Please rely on stated quantity.
FDA Statement of Identity
Dietary Supplement
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
K2-D3 with Astaxanthin by Douglas Laboratories label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in K2-D3 with Astaxanthin by Douglas Laboratories
These are the 3 active ingredients this product is made of. Select any to open its full monograph.
Serving size1 Vegetarian Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.
Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.
Vitamin D3
Interacts with715 drugs
Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people,...
Vitamin D3 monograph & interactionsVitamin K2
Interacts with2 drugs
Vitamin K is an essential nutrient your body needs for normal blood clotting and to support healthy bones. Most people get enough from food, but suppl...
Vitamin K2 monograph & interactionsAstaReal
Interacts with671 drugs
Astaxanthin is a reddish carotenoid pigment with strong antioxidant activity in the lab, and it is widely promoted for skin, eye, heart, and exercise...
AstaReal monograph & interactionsOther (inactive) ingredients: Microcrystalline Cellulose, Hydroxypropyl Methylcellulose, Vegetable Stearate. These complete the product’s ingredient list but are not active constituents.
K2-D3 with Astaxanthin by Douglas Laboratories Drug Interactions
HelloPharmacist Interaction Report
Douglas Laboratories' K2-D3 with Astaxanthin does interact with medications, primarily through its vitamin D3 and vitamin K2 content.
The most serious interaction is vitamin K2 with warfarin (Coumadin), a blood thinner — vitamin K can reverse warfarin's ability to prevent blood clots, which could be dangerous. Vitamin K2 is the ingredient responsible for this Major-severity interaction.
Read the full breakdown — every affected drug type, severity by severity
Vitamin D3 carries Moderate interactions with several drug types. These include thiazide diuretics (water pills that lower blood pressure), which can combine with high-dose vitamin D to raise calcium levels too high in your blood (hypercalcemia); calcium-channel blockers like verapamil and diltiazem, used for heart rhythm and blood pressure, where high-dose vitamin D can reduce their effectiveness; digoxin (a heart medication), where elevated calcium from vitamin D increases the risk of dangerous heart rhythms; atorvastatin (Lipitor), a cholesterol drug that vitamin D may reduce absorption of; calcipotriene, a topical vitamin D-like psoriasis treatment that can cause hypercalcemia if combined with supplements; and aluminum-containing products, which vitamin D may help your body absorb too much of.
Vitamin D also carries a Minor interaction with CYP3A4 substrates — a large group of medications metabolized by a liver enzyme that vitamin D may induce.
Astaxanthin carries Moderate interactions with CYP3A4 and CYP2B6 substrates — two enzyme families that break down many drugs. These effects haven't been observed in humans yet, only in laboratory research.
Altogether, these interactions span 744 individual medications. Use the medication checker on this page to search your exact prescriptions before starting this product.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against K2-D3 with Astaxanthin?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in K2-D3 with Astaxanthin interact with 743 drugs. Click any drug to see the details.
3 of the 3 ingredients in K2-D3 with Astaxanthin interact with drugs. Each result below shows which ingredient is responsible. Vitamin D3 AstaReal Vitamin K2
Amiloride, HydrochlorothiazideAmil-Co, Amilzide, Moduret 25, Moduretic
How Amiloride, Hydrochlorothiazide interacts with K2-D3 with Astaxanthin — through 1 ingredient. Tap an ingredient for the detail:
Vitamin D3Thiazide Diuretics Moderate
Interaction Summary
Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Read the full Vitamin D3 + Amiloride, Hydrochlorothiazide interactionAmiodaroneCordarone, Pacerone
How Amiodarone interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amiodarone interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amiodarone interactionAmitriptylineElavil
How Amitriptyline interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amitriptyline interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amitriptyline interactionAmitriptyline, ChlordiazepoxideLimbitrol DS
How Amitriptyline, Chlordiazepoxide interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amitriptyline, Chlordiazepoxide interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amitriptyline, Chlordiazepoxide interactionAmitriptyline, PerphenazineEtrafon, Etrafon-A, Etrafon-Forte, Triavil
How Amitriptyline, Perphenazine interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amitriptyline, Perphenazine interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amitriptyline, Perphenazine interactionAmlodipineNorliqva
How Amlodipine interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine interactionAmlodipine BenzoateKaterzia
How Amlodipine Benzoate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine Benzoate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine Benzoate interactionAmlodipine BesilateIstin
How Amlodipine Besilate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine Besilate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine Besilate interactionAmlodipine BesylateNorvasc
How Amlodipine Besylate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine Besylate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine Besylate interactionAmlodipine Besylate, BenazeprilLotrel
How Amlodipine Besylate, Benazepril interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine Besylate, Benazepril interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine Besylate, Benazepril interactionAmlodipine, CelecoxibConsensi
How Amlodipine, Celecoxib interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amlodipine, Celecoxib interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amlodipine, Celecoxib interactionAmobarbital, SecobarbitalTuinal
How Amobarbital, Secobarbital interacts with K2-D3 with Astaxanthin — through 1 ingredient. Tap an ingredient for the detail:
AstarealCytochrome P450 2b6 (cyp2b6) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP2B6.
Read the full Astareal + Amobarbital, Secobarbital interactionAmoxicillin, Omeprazole Magnesium, RifabutinTalicia
How Amoxicillin, Omeprazole Magnesium, Rifabutin interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amoxicillin, Omeprazole Magnesium, Rifabutin interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amoxicillin, Omeprazole Magnesium, Rifabutin interactionAmprenavirAgenerase
How Amprenavir interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Amprenavir interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Amprenavir interactionApalutamideErleada
How Apalutamide interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Apalutamide interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Apalutamide interactionApixabanEliquis
How Apixaban interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Apixaban interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Apixaban interactionApremilastOtezla
How Apremilast interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Apremilast interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Apremilast interactionAprepitantCinvanti, Emend
How Aprepitant interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aprepitant interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aprepitant interactionAprobarbital, Butabarbital, PhenobarbitalTriple Barbital
How Aprobarbital, Butabarbital, Phenobarbital interacts with K2-D3 with Astaxanthin — through 1 ingredient. Tap an ingredient for the detail:
AstarealCytochrome P450 2b6 (cyp2b6) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP2B6.
Read the full Astareal + Aprobarbital, Butabarbital, Phenobarbital interactionAripiprazoleAbilify, Abilify Maintena, Abilify Mycite
How Aripiprazole interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aripiprazole interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aripiprazole interactionAripiprazole LauroxilAristada, Aristada Initio Kit
How Aripiprazole Lauroxil interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aripiprazole Lauroxil interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aripiprazole Lauroxil interactionArmodafinilNuvigil
How Armodafinil interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Armodafinil interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Armodafinil interactionAspirin, Aluminum Hydroxide, Codeine Phosphate, Magnesium HydroxideAscriptin Codeine #3
How Aspirin, Aluminum Hydroxide, Codeine Phosphate, Magnesium Hydroxide interacts with K2-D3 with Astaxanthin — through 1 ingredient. Tap an ingredient for the detail:
Vitamin D3Aluminum Moderate
Interaction Summary
Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
Read the full Vitamin D3 + Aspirin, Aluminum Hydroxide, Codeine Phosphate, Magnesium Hydroxide interactionAspirin, Butalbital, CaffeineFiorinal
How Aspirin, Butalbital, Caffeine interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Butalbital, Caffeine interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Butalbital, Caffeine interactionAspirin, Butalbital, Caffeine, Codeine PhosphateFiorinal w/ Codeine
How Aspirin, Butalbital, Caffeine, Codeine Phosphate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Butalbital, Caffeine, Codeine Phosphate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Butalbital, Caffeine, Codeine Phosphate interactionAspirin, Butalbital, Caffeine, PhenacetinMarnal
How Aspirin, Butalbital, Caffeine, Phenacetin interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Butalbital, Caffeine, Phenacetin interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Butalbital, Caffeine, Phenacetin interactionAspirin, CaffeineAnacin
How Aspirin, Caffeine interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Caffeine interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Caffeine interactionAspirin, Caffeine, Codeine PhosphateAnacin w/ Codeine
How Aspirin, Caffeine, Codeine Phosphate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Caffeine, Codeine Phosphate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Caffeine, Codeine Phosphate interactionAspirin, Caffeine, Dihydrocodeine BitartrateSynalgos DC
How Aspirin, Caffeine, Dihydrocodeine Bitartrate interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Caffeine, Dihydrocodeine Bitartrate interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Caffeine, Dihydrocodeine Bitartrate interactionAspirin, Caffeine, Dover's PwdAcedoval, Dovacet
How Aspirin, Caffeine, Dover's Pwd interacts with K2-D3 with Astaxanthin — through 2 ingredients. Tap an ingredient for the detail:
AstarealCytochrome P450 3a4 (cyp3a4) Substrates Moderate
Interaction Summary
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
Read the full Astareal + Aspirin, Caffeine, Dover's Pwd interactionVitamin D3Cytochrome P450 3a4 (cyp3a4) Substrates Minor
Interaction Summary
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
Read the full Vitamin D3 + Aspirin, Caffeine, Dover's Pwd interactionEach ingredient & the kinds of drugs it affects
For each ingredient in K2-D3 with Astaxanthin with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.
Vitamin D3
Aluminum
Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
The protein that transports calcium across the intestinal wall can also bind and transport aluminum. This protein is stimulated by vitamin D, which may therefore increase aluminum absorption. This mechanism may contribute to increased aluminum levels and toxicity in people with renal failure, when they take vitamin D and aluminum-containing phosphate binders chronically.
Atorvastatin (Lipitor)
Vitamin D might reduce absorption of atorvastatin.
A small, low-quality clinical study shows that taking vitamin D reduces levels of atorvastatin and its active metabolites by up to 55%. However, while atorvastatin levels decreased, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels did not substantially change. Atorvastatin is metabolized in the gut by CYP3A4 enzymes, and researchers theorized that vitamin D might induce CYP3A4, causing reduced levels of atorvastatin. However, this proposed mechanism was not specifically studied.
Calcipotriene (Dovonex)
Taking calcipotriene with vitamin D increases the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with vitamin D supplements might increase the risk of hypercalcemia.
Digoxin (Lanoxin)
Theoretically, hypercalcemia induced by high-dose vitamin D can increase the risk of arrhythmia from digoxin.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and digoxin concurrently.
Diltiazem (Cardizem, Others)
Theoretically, hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of diltiazem for arrhythmia.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically this could also occur with diltiazem. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and diltiazem concurrently.
Thiazide Diuretics
Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Thiazide diuretics decrease urinary calcium excretion, which could lead to hypercalcemia if vitamin D supplements are taken concurrently. This has been reported in people being treated with vitamin D for hypoparathyroidism, and also in elderly people with normal parathyroid function who were taking a thiazide, vitamin D, and calcium-containing antacids daily.
Verapamil (Calan, Others)
Hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of verapamil for arrhythmia.
Hypercalcemia due to high doses of vitamin D can reduce the effectiveness of verapamil in atrial fibrillation. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and verapamil concurrently.
Cytochrome P450 3A4 (Cyp3A4) Substrates
Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
There is some concern that vitamin D might induce CYP3A4. In vitro research suggests that vitamin D induces CYP3A4 transcription. Additionally, observational research has found that increased UV light exposure and serum vitamin D levels are associated with decreased serum levels of CYP3A4 substrates such as tacrolimus and sirolimus, while no association between UV light exposure or vitamin D levels and levels of mycophenolic acid, a non-CYP3A4 substrate, was found. A small, low-quality clinical study shows that taking vitamin D reduces levels of the CYP3A4 substrate atorvastatin and its active metabolites by up to 55%; however, the clinical effects of atorvastatin were not reduced. While researchers theorized that vitamin D might induce CYP3A4, this proposed mechanism was not specifically studied.
AstaReal
Cytochrome P450 2B6 (Cyp2B6) Substrates
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP2B6.
In vitro research shows that astaxanthin induces cytochrome CYP2B6 enzyme activity in human hepatocytes. This effect has not been reported in humans.
Cytochrome P450 3A4 (Cyp3A4) Substrates
Theoretically, astaxanthin may decrease levels of drugs metabolized by CYP3A4.
In vitro research shows that astaxanthin induces CYP3A4 enzyme activity in human hepatocytes. This effect has not been reported in humans.
Vitamin K2
Warfarin (Coumadin)
Vitamin K can antagonize and reverse the therapeutic effects of warfarin.
Vitamin K antagonizes the effects of warfarin. Excessive vitamin K intake, either from supplements or from changes in the diet, can reduce the anticoagulant effect of warfarin.
Brand information
Manufacturer and brand details for K2-D3 with Astaxanthin, from the product label.
Douglas Laboratories
See all Douglas Laboratories products- Name
- Douglas Laboratories
- Street Address
- 600 Boyce Road
- City
- Pittsburgh
- State
- PA
- ZipCode
- 15205
- Phone Number
- 1.800.245.4440
- Web Address
- www.douglaslabs.com
K2-D3 with Astaxanthin by Douglas Laboratories: Common Questions
Does K2-D3 with Astaxanthin by Douglas Laboratories interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
Can I take this if I'm on warfarin?
Is astaxanthin safe during pregnancy?
What are the most common side effects?
What does vitamin K2 do in this product?
Does astaxanthin actually work for anti-aging or brain health?
Can I take this with my cholesterol medication?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if K2-D3 with Astaxanthin is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind K2-D3 with Astaxanthin’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Vitamin D
Interacts with 715 drugsVitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people, especially those with low sun exposure,...
Read the full Vitamin D monograph → Herb & supplement monographVitamin K
Interacts with 2 drugsVitamin K is an essential nutrient your body needs for normal blood clotting and to support healthy bones. Most people get enough from food, but supplements are sometimes used for deficiency...
Read the full Vitamin K monograph → Herb & supplement monographAstaxanthin
Interacts with 671 drugsAstaxanthin is a reddish carotenoid pigment with strong antioxidant activity in the lab, and it is widely promoted for skin, eye, heart, and exercise benefits. Early human studies are promis...
Read the full Astaxanthin monograph →Sources & How We Checked
K2-D3 with Astaxanthin's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 40 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Vitamin D 26 references
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
- Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. PubMed
- Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
- Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
- Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
- Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Ann Intern Med 1972;77:557-63. PubMed
- Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19(11):191105.
- Moon J. The role of vitamin D in toxic metal absorption. J Am Coll Nutr 1994;13:559-64.
- Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1alphaOH vitamin D<SUB>3</SUB> increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
- Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13. PubMed
- Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. PubMed
- Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
- Cox KA, Dunn MA. Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. J Nutr 2001;131:2007-13. PubMed
- Escribano, J., Balaguer, A., Pagone, F., Feliu, A., and Roque, I. Figuls. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane.Database.Syst.Rev. 2009;(1):CD004754. PubMed
- Carlton, S., Clopton, D., and Cappuzzo, K. A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult Pharm 2010;25(3):171-177. PubMed
- Wang, H., Xia, N., Yang, Y., and Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42. PubMed
- Turner AN, Carr Reese P, Fields KS, Anderson J, Ervin M, Davis JA, Fichorova RN, Roberts MW, Klebanoff MA, Jackson RD. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet G PubMed
- Weiner M, Epstein FH. Signs and symptoms of electrolyte disorders. Yale J Biol Med. 1970;43(2):76-109.
- Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
- Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. PubMed
- Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA. 2021.
- Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 2013;136:54-8. PubMed
- Doyle D, Browne U, Brickley A, Murphy D. Vitamin D-induced hypercalcaemia and acute kidney injury in sarcoidosis. BMJ Case Rep 2023;16(1):e250580. PubMed
- Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev 2023;2(2):CD011511. PubMed
- Kinesya E, Santoso D, Gde Arya N, et al. Vitamin D as adjuvant therapy for diabetic foot ulcers: Systematic review and meta-analysis approach. Clin Nutr ESPEN 2023;54:137-143. PubMed
Vitamin K 11 references
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
- Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293-300. PubMed
- Dietary vitamin K guidance: an effective strategy for stable control of oral anticoagulation? Nutr Rev. 2010;68(3):178-81. PubMed
- Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul;41(7):715-22. PubMed
- Riegert-Johnson, D. L. and Volcheck, G. W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann.Allergy Asthma Immunol. 2002;89(4):400-406. PubMed
- Dezee, K. J., Shimeall, W. T., Douglas, K. M., Shumway, N. M., and O'malley, P. G. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch.Intern.Med. 2-27-2006;166(4):391-397. DOI
- Dentali, F., Ageno, W., and Crowther, M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J.Thromb.Haemost. 2006;4(9):1853-1863. PubMed
- Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29(7):1385-90.
- Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(3):1175-86. PubMed
- Hunnali CR, Devi U, Kitchanan S, Sethuraman G. Three Different Regimens for Vitamin K Birth Prophylaxis in Infants Born Preterm: A Randomized Clinical Trial. J Pediatr 2023;255:98-104. PubMed
Astaxanthin 3 references
- Kupcinskas L, Lafolie P, Lignell A, et al. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled
- Kistler, A., Liechti, H., Pichard, L., Wolz, E., Oesterhelt, G., Hayes, A., and Maurel, P. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch.Toxicol. 2002;75(11-12):665-675. PubMed
- Choi HD, Youn YK, Shin WG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. Plant Foods Hum Nutr. 2011;66:363-369. PubMed
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC